Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-895 phase 2 multicenter study in myelofibrosis, indolent systemic mastocytosis, and mast cell activation syndrome
2024-514467-26-00Phase 2Authorised
- Sponsor
- Telios Pharma
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2 trial of TL-895 in myelofibrosis (MF), indolent systemic mastocytosis (ISM) and Mast Cell Activation Syndrome (MCAS) (7 arms), sponsored by Telios Pharma. Planned start Apr 2021; status: authorised.
02
Drugs
TL-895
03
Conditions
myelofibrosis (MF)indolent systemic mastocytosis (ISM)Mast Cell Activation Syndrome (MCAS)
Beyond the preview
Go deeper on 2024-514467-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514467-26-00.